Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : URMD -- Huge market potential -- Ignore unavailable to you. Want to Upgrade?

To: Chris Odom who wrote (261)	4/17/1998 11:25:00 AM
From: Ken M	Read Replies (1) \| Respond to of 369

TABLE - UroMed Corp (NASDAQ:URMD) Q1 loss narrows Reuters, Friday, April 17, 1998 at 11:13 NEEDHAM, Mass., April 17 (Reuters) - (In thousands, except share data) Three Months Ended March 31, 1998 1997 Revenues $ 61 $ 263 Costs and expenses: Cost of revenues 1,135 1,001 Research and development 1,921 2,308 Marketing and sales 1,764 4,136 General and administrative 1,077 1,317 Restructuring 1,024 --- Total costs and expenses 6,921 8,762 Loss from operations (6,860) (8,499) Interest income 897 1,302 Interest expense (1,134) (1,134) Net loss (7,097) (8,331) Basic and diluted net loss per share (.27) (.31) Weighted average common shares outstanding 26,773,712 26,488,618